Saturday 17 October 2026
Export OMDA’s income statement to Excel — free account
Omada Health, Inc.
OMDA Healthcare Health Information Services
Omada Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $260.2 million, up 53.2% from fiscal 2024. In the quarter to June 2026, revenue grew 43.1%, EPS grew 137.5% and free cash flow grew 45.7%, each against the same quarter a year earlier.
17.63
1.04
−5.57%
Follow OMDA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
313.57 | 0.00 | 0.00 | 0.00 |
+6 more quarters Free account |
P/S ratio |
4.23 | 2.61 | 2.22 | 5.55 | |
P/FCF ratio |
76.47 | 45.17 | 46.55 | 0.00 | |
P/Operating CF |
326.95 | (62.59) | 27.04 | 125.81 | |
P/B ratio |
5.18 | 3.16 | 2.52 | 5.87 | |
Price to Tangible BV |
5.51 | 3.38 | 2.70 | 6.33 | |
EV/Sales |
3.61 | 1.97 | 1.48 | 4.81 | |
EV/EBITDA |
121.98 | 533.27 | 0.00 | 0.00 | |
EV/Operating CF |
47.22 | 24.80 | 21.15 | (115.06) | |
EV/FCF |
65.28 | 34.09 | 31.09 | (73.41) | |
Quick Ratio |
3.69 | 3.67 | 3.39 | 3.42 | |
Current Ratio |
3.91 | 3.92 | 3.60 | 3.64 | |
Net Debt/EBITDA |
(36.36) | 91.48 | (39.65) | 923.85 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.98 | 1.87 | 1.70 | 1.60 | |
Operating CF/Net income |
0.76 | 3.98 | 4.14 | (3.19) | |
Capex/Depreciation |
(0.65) | (0.63) | (0.58) | (0.86) | |
Interest Coverage |
253.50 | (265.61) | 252.38 | (7.12) | |
Research and Development Expense of Revenue |
16.65% | 16.27% | 15.23% | 15.14% | |
Selling, General and Administrative Expense of Revenue |
51.93% | 52.25% | 51.19% | 54.80% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.06 | |
Share Based Compensation of Revenue |
6.41% | 5.39% | 4.94% | 5.20% | |
Graham Net Nets |
0.17 | 0.27 | 0.34 | 0.14 | |
Graham Number |
2.58 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
0.32% | (2.07%) | (8.60%) | (11.90%) | |
Free Cash Flow Yield |
1.31% | 2.21% | 2.15% | (1.18%) | |
Revenue per Share |
1.47 | 1.32 | 2.07 | 1.18 | |
Operating CF per Share |
0.07 | (0.20) | 0.58 | 0.18 | |
Capex per Share |
(0.03) | (0.03) | (0.04) | (0.03) | |
Free Cash Flow per Share |
0.04 | (0.23) | 0.55 | 0.14 | |
Cash per Share |
3.71 | 3.59 | 6.06 | 3.44 | |
Shareholders Equity per Share |
4.23 | 3.97 | 6.27 | 3.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.23 | 3.97 | 6.27 | 3.77 | |
Free Cash Flow |
2.34 | (13.39) | 20.03 | 8.15 | |
Working Capital |
219.43 | 200.75 | 197.21 | 184.78 | |
Capital Expenditures |
(1.66) | (1.56) | (1.35) | (1.99) | |
Net Current Asset Value |
219.43 | 200.75 | 197.21 | 184.78 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
44.93 | 31.70 | — | — | |
Average Payables |
9.60 | 6.13 | — | — | |
Average Inventory |
3.79 | 3.56 | — | — | |
Average Assets |
315.60 | 151.40 | 152.70 | 143.73 | |
Average Common Equity |
233.48 | (75.14) | — | — |
Columns are period end dates